Artiva Biotherapeutics, Inc.
ARTV · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -99.3% | 579.2% | 146.3% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -25,837.1% | -84.8% | -1,189.8% | -3,575.3% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -23,304% | -82.7% | -1,184.1% | -3,587.7% |
| EPS Diluted | -5.2 | -1.19 | -3.32 | -4.08 |
| % Growth | -337% | 64.2% | 18.6% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |